Bradley Pharmaceuticals Inc announced that as part of an aggressive global expansion program, Bradley International signed 3 agreements that will provide significant opportunities for international growth.

The first agreement is with CCI, a company specializing in registering and marketing pharmaceutical brands in Eastern Europe and Newly Independent States (EE/NIS). CCI will serve as master distributor, coordinating market analysis, product registrations and advertising in these countries to facilitate an efficient entry into these markets. The EE/NIS consists of 22 countries with a combined population of 300 million people. These markets represent tremendous potential for international expansion of Bradley therapies. CCI has begun market analysis and sales projections for the initial Bradley brands to be introduced to these regions, including the Carmol 40 line, Trans-Ver-Sal, Entsol and Lubrin.

Agreements also have been signed with Aktive Enterprises in Taiwan and Naveh Wholesale in Israel. Aktive has been distributing pharmaceuticals in Taiwan for over 40 years, with current annual sales of $12 million (US). Aktive will begin registration of Pamine and add more Bradley products in the future.

Naveh Wholesale, specializing in the Ear, Nose and Throat (ENT) niche market, currently distributes to over 700 retail and chain pharmacies in Israel. Naveh will focus on marketing and distributing Entsol.

President and CEO Daniel Glassman stated, "Bradley is excited to have signed agreements with three new distributors. These international partners provide the Company with significant potential to rapidly increase global distribution of many Bradley brands."